ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. | ABOS | United States of America | $176.87M | 389 |
| Corbus Pharmaceuticals Holdings, Inc. | CRBP | United States of America | $158.04M | 830 |
| ACHIEVE LIFE SCIENCES, INC. | ACHV | United States of America | $642.41M | 1,304 |
| NEONC TECHNOLOGIES HOLDINGS, INC. | NTHI | United States of America | $171.55M | 196 |
| AGENUS INC | AGEN | United States of America | $134.92M | 2,324 |
| Nkarta, Inc. | NKTX | United States of America | $179.58M | 463 |
| Whitehawk Therapeutics, Inc. | WHWK | United States of America | $206.96M | 634 |
| Korro Bio, Inc. | KRRO | United States of America | $212.30M | 839 |
| Connect Biopharma Holdings Ltd | CNTB | United States of America | $162.12M | 215 |
| Medigen Biotechnology Corporation | 3176 | Taiwan | $144.15M | 1,918 |
| UnicoCell Biomed Inc. | 6794 | Taiwan | $163.68M | 609 |
| vTv Therapeutics Inc. | VTVT | United States of America | $159.63M | 600 |
| SCANCELL HOLDINGS PLC | SCLP | United Kingdom | $159.24M | 470 |
| Tiziana Life Sciences Ltd | TLSA | Bermuda | $156.53M | 488 |
| Sagimet Biosciences Inc. | SGMT | United States of America | $455.11M | 291 |
| Cardiol Therapeutics Inc. | CRDL | Canada | $121.04M | 649 |
| Cartesian Therapeutics, Inc. | RNAC | United States of America | $155.08M | 908 |
| Heidelberg Pharma AG | HPHA | Germany | $151.47M | 839 |
| BioInvent International | BINV | Sweden | $153.52M | 742 |
| IMMUNIC, INC. | IMUX | United States of America | $201.19M | 888 |
| Spero Therapeutics, Inc. | SPRO | United States of America | $121.59M | 522 |
| Tenaya Therapeutics, Inc. | TNYA | United States of America | $150.73M | 365 |
| Bonus BioGroup Ltd. | BONS | Israel | $99.54M | 2,652 |
| Molecular Partners AG | MOLN | Switzerland | $147.07M | 397 |
| Black Diamond Therapeutics, Inc. | BDTX | United States of America | $112.88M | 502 |
| Oramed Pharmaceuticals Inc. | ORMP | United States of America | $162.52M | 1,697 |
| Formosa Pharmaceuticals, Inc. | 6838 | Taiwan | $118.76M | 531 |
| Mersana Therapeutics, Inc. | MRSN | United States of America | $145.36M | 728 |
| ProQR Therapeutics N.V. | PRQR | Netherlands | $144.34M | 412 |
| GALECTIN THERAPEUTICS INC | GALT | United States of America | $267.38M | 1,476 |
| RYVU Therapeutics S.A. | RVU | Poland | $143.88M | 1,383 |
| Kalaris Therapeutics, Inc. | KLRS | United States of America | $143.76M | 699 |
| FATE THERAPEUTICS INC | FATE | United States of America | $230.79M | 881 |
| Pharmosa Biopharm Inc. | 6875 | Taiwan | $140.93M | 488 |
| PRECISION BIOSCIENCES INC | DTIL | United States of America | $140.69M | 596 |
| Unicycive Therapeutics, Inc. | UNCY | United States of America | $221.88M | 307 |
| Medivir | MVIR | Sweden | $113.08M | 1,103 |
| Equillium, Inc. | EQ | United States of America | $170.71M | 460 |
| Crossject | ALCJ | France | $126.99M | 419 |
| Energenesis Biomedical Co., Ltd. | 6657 | Taiwan | $96.86M | 956 |
| Innate Pharma | IPH | France | $126.06M | 1,614 |
| Bioceltix S.A. | BCX | Poland | $131.88M | 396 |
| MaaT Pharma | MAAT | France | $60.84M | 452 |
| INOVIO PHARMACEUTICALS, INC. | INO | United States of America | $92.15M | 1,306 |
| AN2 Therapeutics, Inc. | ANTX | United States of America | $168.20M | 387 |
| Captor Therapeutics S.A. | CTX | Poland | $128.18M | 707 |
| CYPHERPUNK TECHNOLOGIES INC. | CYPH | United States of America | $116.14M | 649 |
| SANGAMO THERAPEUTICS, INC | SGMO | United States of America | $71.30M | 1,582 |
| FILANA THERAPEUTICS, INC. | FLNA | United States of America | $114.97M | 1,191 |
| PepGen Inc. | PEPG | United States of America | $96.15M | 311 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.